GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine ...

The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...

GSK's depemokimab accepted for review by Health Canada for the treatment of asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps . Contact Cision. 866-245-2317 ...

The late-phase efficacy of benralizumab, depemokimab, and vilobelimab indicate reductions in disease activity and steroid dependence. As newer biologics get ready for approval, ...

GSK's depemokimab accepted for review by Health Canada for the treatment of asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps .

GSK also expects a regulatory decision on depemokimab in December and further pipeline entries such as efimosfermin. Despite the re-rating, GSK shares continue to trade at a discount. Specifically, it ...

GSK also expects a regulatory decision on depemokimab in December and further pipeline entries such as efimosfermin. Despite the re-rating, GSK shares continue to trade at a discount. Specifically, it ...

Investing.com -- Berenberg has lowered its rating on GSK plc (LON:GSK) to Hold from Buy, a move driven by the stock’s strong year-to-date (YTD) performance and an expected pause in investor ...

GSK also expects a regulatory decision on depemokimab in December and further pipeline entries such as efimosfermin. Despite the re-rating, GSK shares continue to trade at a discount.